Navigation Links
Progen Announces PI-88 Phase 2 Lung Cancer Results
Date:9/24/2007

BRISBANE, Sept. 24 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures.

The overall data from this trial suggests that no further investigation of PI-88 in combination with docetaxel in patients with non small cell lung cancer that have failed platinum based first line therapies is warranted. However, nine patients in the study switched to PI-88 after experiencing toxicity or disease progression with docetaxel monotherapy. The data for this patient group suggests a potential survival benefit that Progen intends to investigate further with, amongst others, the clinicians involved in this study.

"We are disappointed, first and foremost, for the patients with non small cell lung cancer that have disease progression following platinum based chemotherapy as treatment options are limited," said Justus Homburg, Progen's Chief Executive Officer. "The outcome of this study has no impact on our Phase 3 registration strategy for patients with post-resection liver cancer which we announced today has been granted fast-track status designation by the U.S. FDA."

"It is quite common for new drugs to show benefit in one patient group but limited benefit in another. To date, PI-88 has shown evidence of benefit in patients with melanoma, multiple myeloma and post-resection liver cancer. In particular, PI-88 may be more active for tumors that are at an earlier disease stage, such as has been demonstrated in the PI-88 Phase 2 primary liver cancer trial" added Homburg. "In that tria
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Calif. , July 31, 2014 Lazarus ... of novel interventional devices to facilitate removal of blood ... Proceeds from the financing will support EU commercialization of ... filings for the Lazarus ReCover™ and Lazarus Cover™ in ... "This financing reflects investor confidence in the value of ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... New York results of AFF008, a ... disease. PD01A is the first therapy against the protein alpha-synuclein, ... The Michael J. Fox Foundation for Parkinson,s Research (MJFF) ... presented at the press conference on the impact a disease-modifying ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... WORTH, Texas, Aug. 24, 2011 The UNT System Board ... authorized in the 82nd Texas legislative session. As part of ... and UNT Dallas, the College of Pharmacy students will earn ... graduate portion of their classes on the UNT Health Science ...
... Technologies, Inc. ( www.heartsine.com ), a world leader in ... the samaritan ® PAD 300P Public Access ... a school serving children and young people with intellectual ... (AED) is now available for Camphill staff enabling ...
Cached Medicine Technology:UNT Regents Approve New College of Pharmacy 2HeartSine® Technologies Donates Lifesaving AED to Camphill Special School 2
(Date:8/1/2014)... US (PRWEB) August 01, 2014 Get ... in partnership with PitchBook presents the 3Q 2014 Private ... U.S private equity investment, exits and fundraising activity in ... insight to help plan for private equity endeavors for ... registration form to download it now. , About Merrill ...
(Date:7/31/2014)... California (PRWEB) July 31, 2014 Serious ... Dead Psychedelic Acid Test concert posters. Owsley Bear Stanley, ... logo for the Grateful Dead. According to Hawley, “The ... to promote acid test parties in San Francisco and ... were printed on three different colors of paper. They ...
(Date:7/31/2014)... Atlanta, GA (PRWEB) July 31, 2014 ... construction camera on its Ponce City Market project ... the historic Sears, Roebuck & Company building into best-in-class ... nears completion, OxBlue reviewed Jamestown’s experience with their construction ... needs. , Jamestown wanted a construction camera ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 United Theological ... 9 a.m. on Monday, September 15, with its 2014 ... Church, 3440 Shroyer Rd., Kettering, OH. Dr. Emma ... in the Emma Toussant Chair will speak on “Unexpected ... Dr. Justes’ teaching and research interests include pastoral care ...
(Date:7/31/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:United Theological Seminary to Open 144th Year 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... News) -- Successful treatment of major depression in mothers also ... a new study. Children of parents with major depression ... This study included 80 women with depression and their ... a U.S. National Institute of Mental Health trial designed to ...
... Scientists have shown that an experimental vaccine against the human ... contagious nonbacterial illnesses that cause diarrhea and vomiting can ... cause the animals any harm. Using a novel viral ... shown promise in other agents designed to fight such infections ...
... the first laparoscopic procedure was performed to remove a ... St. Louis, this breakthrough minimally invasive technique has become ... achievement is celebrated with a series of cutting-edge articles ... published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). ...
... considered a safe procedure, although complications can occur. The ... reports perforation rates of 0.03%-0.8% for diagnostic procedures, and ... perforation are the result of either mechanical disruption of ... a diverticulum, or stretching of the bowel with loops ...
... successfully treated for depression are at higher risk of losing ... study in the March 15, 2011 issue of the journal ... third of those who experience a stroke develop depression, a ... of health and rehabilitation sciences and of medicine at Indiana ...
... Ben-Gurion University of the Negev (BGU) researchers have shown that ... may have Obstructive Sleep Apnea (OSA), which may be the ... study compared men between the ages of 55 and 75 ... BPE and reported nocturia at least once nightly. The comparison ...
Cached Medicine News:Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 2Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 3Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 4Health News:20th anniversary of first laparoscopic nephrectomy 2Health News:Managing post-stroke depression improves physical functioning 2Health News:Managing post-stroke depression improves physical functioning 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: